Zobrazeno 1 - 10
of 18
pro vyhledávání: ''
Autor:
Hiroki Ishihara, Takashi Ikeda, Hiroaki Shimmura, Toshio Takagi, Hideki Ishida, Kazunari Tanabe, Junpei Iizuka, Kazutaka Nakamura, Hidekazu Tachibana, Kazuhiko Yoshida, Hirohito Kobayashi, Hironori Fukuda, Yasunobu Hashimoto, Tsunenori Kondo, Yuki Nemoto
Publikováno v:
Targeted Oncology. 16:493-502
It remains unclear how early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events affects the outcome of previously untreated metastatic renal cell carcinoma (mRCC). To investigate the prognostic impact of the earl
Autor:
Anders Mellemgaard, Ghada F. Ahmed, Xiaoling Ou, Geoffrey R. Oxnard, Kiyotaka Yoh, Toyoaki Hida, Yuichiro Ohe, Hideo Saka, Manabu Hayama, Tomonori Hirashima, Ko Sugibayashi, Takayasu Kurata, Remy B. Verheijen
Publikováno v:
Targeted Oncology
Background Preliminary data suggest that combining savolitinib, a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, a third-generation, irreversible, oral epidermal growth factor receptor-TKI (EGFR-TKI), may overcome
Autor:
Francesco Raspagliesi, Maurizio D'Incalci, Cristina Matteo, Sara Cresta, Tommaso Ceruti, Giuseppa Maltese, Ilaria Sabatucci, Serena Giolitto, Massimo Zucchetti, Domenica Lorusso, Cristina Sonetto, Dominique Ronzulli, Filippo de Braud, Valentina Sinno
Publikováno v:
Targeted Oncology
Background Targeted agents, such as antiangiogenic drugs (e.g., bevacizumab) and poly(ADP-ribose) polymerase inhibitors (e.g., rucaparib), have been shown to improve outcomes in patients with newly diagnosed or recurrent ovarian cancer. Evidence sugg
Autor:
Tadamichi Denda, Kohei Shitara, Hiroyuki Okuda, Takeharu Yamanaka, Akitaka Makiyama, Naoki Izawa, Tomohiro Nishina, Toshiki Masuishi, Takayuki Yoshino, Hironori Yamaguchi, Takako Eguchi Nakajima, Masato Nakamura, Toshikazu Moriwaki, Yu Sunakawa, Kei Muro, Hideo Baba, Ichinosuke Hyodo, Kimio Yonesaka, Kentaro Yamazaki, Chihiro Kondoh
Publikováno v:
Targeted Oncology. 15:623-633
Predictive markers for the clinical outcomes of second-line treatment in patients with metastatic colorectal cancer (mCRC) remain unclear. This retrospective biomarker study was conducted to explore predictive markers for patients with KRAS exon 2 wi
Autor:
Martina Poteti, Roberto Caporale, Zoe Lombardi, Alessandro Tubita, Barbara Scappini, Persio Dello Sbarba, Angela Silvano, Elisabetta Rovida, Antonella Gozzini, Giulia Cheloni, Ignazia Tusa
Publikováno v:
Targeted Oncology
Background The development of molecularly tailored therapeutic agents such as the BCR/ABL-active tyrosine kinase inhibitors (TKi) resulted in an excellent treatment option for chronic myeloid leukemia (CML) patients. However, following TKi discontinu
Autor:
Hong Li, Iris Yeong Fung Sheng, Timothy D. Gilligan, Ruby Gupta, Pedro C. Barata, Moshe Chaim Ornstein, Jaleh Fallah, Allison Martin, Jorge A Garcia, Brian I. Rini, Kimberly D Allman
Publikováno v:
Targeted Oncology. 15:477-483
Despite treatment with abiraterone acetate and prednisone (AA/P), most patients with metastatic hormone sensitive prostate cancer (mHSPC) will develop castration-resistant disease (metastatic castration-resistant prostate cancer [mCRPC]). The early i
Autor:
Baohui Han, Jianlin Xu, Yanwei Zhang, Huimin Wang, Jun Lu, Yuqing Lou, Tianqing Chu, Hua Zhong, Xueyan Zhang, Wei Zhang
Publikováno v:
Targeted Oncology. 15:175-184
Previously, we demonstrated that treatment with gefitinib combined with pemetrexed plus carboplatin chemotherapy improved progression-free survival (PFS) compared to gefitinib or chemotherapy alone in lung adenocarcinoma patients with sensitizing EGF
Autor:
Nolen J. Perualila, Susan Feyerabend, Tetsuro Ito, Karim Fizazi, Peter De Porre, Suzy Van Sanden, Joris Diels, Fred Saad
Publikováno v:
Targeted Oncology
Background LATITUDE was the first phase 3 trial examining the survival benefit of adding abiraterone acetate (AA) + prednisone (P) to androgen-deprivation therapy (ADT) in newly diagnosed metastatic, castration-sensitive prostate cancer (mCSPC). Due
Autor:
Junpei Iizuka, Kazunari Tanabe, Masayoshi Okumi, Kazuhiko Yoshida, Hiroki Ishihara, Tsunenori Kondo, Hironori Fukuda, Hideki Ishida, Hirohito Kobayashi, Toshio Takagi
Publikováno v:
Targeted Oncology. 14:179-186
Patients in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate-risk group have heterogeneous prognoses and thus may benefit from improved risk stratification. The aim of this study was to analyze inflammatory pa
Autor:
Rong Qiao, Shuyuan Wang, Bo Zhang, Jianlin Xu, Baohui Han, Yiming Zhao, Yanwei Zhang, Lele Zhang
Publikováno v:
Targeted Oncology. 14:169-178
Patients harboring concomitant epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) arrangements constitute a small subgroup of non-small-cell lung cancer (NSCLC) patients. The efficacy of EGFR tyrosine kinase inhibi